Opioid Damages and Health Care Costs Recovery Act, 2023, c.28

Section 8

Liability based on risk contribution

Cite as Opioid Damages and Health Care Costs Recovery Act, 2023, c.28, s. 8 · current to December 13, 2023 · read from New Brunswick Acts and Regulations on November 16, 2026

The text

(1) This section applies to an action for the recovery of the cost of health care benefits or for damages alleged to have been caused or contributed to by an opioid-related wrong, other than an action for the recovery of the cost of health care benefits on an aggregate basis. (2) The court may find each defendant that caused or contributed to the risk of disease, injury or illness liable for a proportion of the damages or cost of health care benefits incurred equal to the proportion of its contribution to that risk of disease, injury or illness if the Crown in right of the Province is unable to establish which defendant caused or contributed to the use or exposure described in paragraph (b) and, as a result of a breach of a common law, equitable or statutory duty or obligation, (a) one or more defendants causes or contributes to a risk of disease, injury or illness by making a type of opioid product available to insured persons, and (b) an insured person has used or been exposed to the type of opioid product referred to in paragraph (a) and suffers disease, injury or illness as a result of the use or exposure. (3) In apportioning liability under subsection (2), the court may consider the following factors: (a) the length of time a defendant engaged in the conduct that caused or contributed to the risk of disease, injury or illness; (b) the market share a defendant had in the type of opioid product that caused or contributed to the risk of disease, injury or illness; (c) the degree of potency of the opioid product manufactured or promoted by a defendant; (d) the amount spent by a defendant on promoting the type of opioid product that caused or contributed to the risk of disease, injury or illness; (e) the degree to which a defendant collaborated or acted in concert with other manufacturers, wholesalers or consultants in any conduct that caused, contributed to or aggravated the risk of disease, injury or illness; (f) the extent to which a defendant conducted tests and studies to determine the risk of disease, injury or illness resulting from use of or exposure to the type of opioid product; (g) the extent to which a defendant assumed a leadership role in manufacturing or promoting the type of opioid product; (h) the efforts a defendant made to warn health care providers and the public about the risk of disease, injury or illness resulting from use of or exposure to the type of opioid product; (i) the extent to which a defendant continued manufacturing or promoting the type of opioid product after it knew or ought to have known the risk of disease, injury or illness resulting from use of or exposure to the type of opioid product; (j) the extent to which a defendant continued promoting the type of opioid product after it knew or ought to have known that the amount or dosage of the type of opioid product promoted did not reasonably reflect the health needs of the population of insured persons who were likely to use or be exposed to the type of opioid product; (k) affirmative steps that a defendant took to reduce the risk of disease, injury or illness to the public; and (l) other factors that are determined to be relevant by the court.
Read the Opioid Damages and Health Care Costs Recovery Act on the Province's website ↗